Novavax, Inc. (NASDAQ:NVAX) reported the commencement of a Phase II clinical study of its RSV F Vaccine in people 60 years of age and older. The goal of the study is to assess immunogenicity and safety to one and two dosage plan of the RSV F Vaccine, without and with aluminum phosphate or Matrix-M(TM) adjuvant, in older people.
The study is an observer-blinded, randomized, placebo-controlled study intended to register up to 300 older subjects in the Southern Hemisphere. Older adults are being registered and vaccinated external to the RSV season to assess immunogenicity. Top-line data are anticipated in 3Q2017.
The management view
Stanley C. Erck, the CEO and President of Novavax, said that they consider that a more immunogenic vaccine in this group of older adult should translate into an efficacious vaccine. They anticipate the report from this study to inform the subsequent steps in older adults’ plan, and would ensure they maintain their leadership position in this attractive market opportunity.
Respiratory syncytial virus, usually stated RSV, is a respiratory infectious ailment that causes grave infection of the respiratory tract, just like influenza. In certain cases, RSV may evolve in severity, and result in hospitalization or also death. The RSV spread occurs yearly, with an incidence pace of 2.5 million infections annually in the U.S. It is gradually being accepted as a major cause of mortality and morbidity in the populace of 64 million adults of age 60 years or more.
Each year, RSV is accountable for almost 16,000 deaths and 207,000 hospitalizations amid adults older than 65. Yearly, there are about 900,000 medical interventions right caused by RSV disease. Presently, there is no permitted RSV vaccine available.
In the last trading session, the stock price of Novavax surged over 2% to close the day at $1.31. The market cap of firm now stands at 341.97 million.